Climb Bio Inc. (CLYM) 12-Month Stock Forecast & Price Target Cone

The CLYM carries an RQD Score of 29 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars, each scored out of 20, are:

• Fundamental Cash Engine: 4 / 20. ROIC is -35% and FCF yield is -9.19%. This is the weakest pillar and indicates the business is consuming rather than generating cash on a return basis.
• Whale 13F Flow: 6 / 20. this pillar reflects institutional accumulation and options positioning.
• Insider Conviction: 3 / 20. this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the second-weakest score, suggesting limited insider-side conviction signals in the rating's inputs.
• Macro Regime Fit: 6 / 20. beta is 1.0 with a sector-sensitivity read. The score is moderate-to-weak.
• Forensic Balance Sheet: 10 / 20. Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. This is the strongest pillar, but it is still only half-credit.

Taken together, the pillars indicate that the rating's weakest inputs are operating cash generation and insider conviction, while the balance sheet offers partial support. For a prospective investor evaluating the stock today, the implication is that the rating frames CLYM as high-risk on current fundamentals. Upside drivers would have to come from catalysts that the cash-engine and insider pillars do not yet reflect. Valuation tradeoffs are difficult to assess because the source data lacks earnings-based multiples, so the price of $10.33 cannot be benchmarked against earnings. This is an educational reading of the rating, not personalized financial advice.

Climb Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. Reported revenue is — in each of the three listed fiscal years, indicating no reported revenue in the source period. The company's market capitalization is $0.6B.

The company reported operating losses and net losses in all three periods, with FY 2025 operating loss at -$67.9M and net loss at -$59.9M. ROIC is -35%, and per the market data, gross, operating, and net margins are each 0%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5. Cash declined from $87.2M in FY 2024 to $35.7M in FY 2025 .

• 🐂 Primary Bull Case: Balance sheet and a cited Deutsche Bank Buy initiation on the autoimmune pipeline offer partial support against weak cash flows. With Fundamental Cash Engine at 4/20 (ROIC -35.0%, FCF yield -9.19%) and Institutional Whale Flow at 6/20, sustained execution supports upside toward the top of the $1.63 – $18.33 52-week range.
• 🐻 Primary Bear Case: ROIC of -35%, FCF yield of -9.19%, and three consecutive years of operating losses leave the cash engine unproven. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), CLYM carries a macro regime beta of 1.00 and gross margin of —.

• Key Question #1: Why are EPS, P/E, and EV/EBITDA unavailable, and how should valuation be assessed without earnings-based multiples?
• Key Question #2: What drove the 52-week range spanning $1.63 to $18.33, and what institutional or insider activity accompanied that move?
• Key Question #3: What is the basis for the Deutsche Bank Buy initiation referenced in the news feed, and does that view appear in the analyst data?